AAC
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuan, M.
Right arrow Articles by Livermore, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, M.
Right arrow Articles by Livermore, D. M.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2001, p. 309-311, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.309-311.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

SHV-14, a Novel beta -Lactamase Variant in Klebsiella pneumoniae Isolates from Nijmegen, The Netherlands

Meifang Yuan,1,dagger Lucinda M. C. Hall,1 Jaa Hoogkamp-Korstanje,2 and David M. Livermore3,*

Department of Medical Microbiology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London E1 2AD,1 and Antibiotic Resistance Monitoring & Reference Laboratory, Central Public Health Laboratory, London NW9 5HT,3 United Kingdom, and Department of Medical Microbiology, University Hospital St. Radboud, Nijmegen, The Netherlands2

Received 11 April 2000/Returned for modification 11 August 2000/Accepted 6 October 2000

Four ceftazidime-resistant isolates of a Klebsiella pneumoniae strain were collected from intensive care unit patients in Nijmegen, The Netherlands. These isolates had TEM-29 and SHV-14 beta -lactamases. SHV-14 is a novel variant, with two substitutions compared with the sequence of SHV-1: Ile8Phe and Arg43Ser. Its gene also had a silent Cright-arrowT mutation at nucleotide 481. The SHV-14 enzyme had slightly higher Vmax rates than SHV-1 for oxyimino-aminothiazolyl cephalosporins, but this activity was insufficient for the enzyme to count as an extended-spectrum beta -lactamase.

* Corresponding author. Mailing address: Antibiotic Resistance Monitoring and Reference Laboratory, Central Public Health Laboratory, 61 Colindale Ave., London NW9 5HT, United Kingdom. Phone: 0208-200-4400, ext. 4223. Fax: 0208-358 3292. E-mail: DLivermore{at}phls.nhs.uk.

dagger Present address: Molecular Genetics and Oncology Group, Department of Clinical Dental Sciences, The University of Liverpool, Liverpool L69 3BX, United Kingdom.

Antimicrobial Agents and Chemotherapy, January 2001, p. 309-311, Vol. 45, No. 1
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.1.309-311.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:



Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Clin. Vaccine Immunol. Clin. Microbiol. Rev.
J. Clin. Microbiol. ALL ASM JOURNALS

Copyright © 2001 by the American Society for Microbiology. All rights reserved.